Catabasis Pharmaceuticals Appoints Gregg Lapointe to its Board of Directors
January 04 2019 - 8:00AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced the appointment of Gregg
Lapointe to its Board of Directors. Mr. Lapointe has three decades
of commercial and financial experience and he is Co-Founder and
Chief Executive Officer of Cerium Pharmaceuticals, Inc., a
biopharmaceutical company focused on developing and commercializing
medicines for patients with rare diseases.
“Gregg’s broad set of experiences as a leader and a director
makes him an excellent addition to our board of directors,” said
Ken Bate, co-Chairman of Catabasis’ Board of Directors. “His past
roles involving commercial operations and rare diseases will be
very valuable as we move through Phase 3 and prepare for a
commercial launch of our lead program edasalonexent.”
“I am incredibly excited at the potential for edasalonexent to
have a significant impact on the treatment landscape for Duchenne
muscular dystrophy, and I look forward to contributing my expertise
as Catabasis prepares to bring this novel therapy to all that could
benefit,” said Gregg Lapointe.
Mr. Lapointe currently serves on the Board of Directors of
Cytori Therapeutics, Inc., Soligenix, Inc., and Rigel
Pharmaceuticals, Inc. Prior to founding Cerium Pharmaceuticals, Mr.
Lapointe served as Chief Executive Officer of Sigma-Tau
Pharmaceuticals, Inc., a private biopharmaceutical company, from
2008 to 2012 as well as Chief Operating Officer from 2003 to 2008.
Mr. Lapointe holds a Bachelor of Commerce from Concordia University
(Montreal), a graduate diploma in Accountancy from McGill
University (Montreal), an MBA from Duke University and is a CPA
(Illinois).
About CatabasisAt Catabasis Pharmaceuticals, our mission
is to bring hope and life-changing therapies to patients and their
families. Our lead program is edasalonexent, an NF-kB inhibitor in
development for the treatment of Duchenne muscular dystrophy. Our
global Phase 3 PolarisDMD trial is currently enrolling boys
affected by Duchenne. For more information on edasalonexent and our
Phase 3 PolarisDMD trial, please visit www.catabasis.com or
www.twitter.com/catabasispharma.
Forward Looking StatementsAny statements in this press
release about future expectations, plans and prospects for the
Company, including statements about future clinical trial plans
including, among other things, statements about the Company’s
global Phase 3 PolarisDMD trial in DMD to evaluate the efficacy and
safety of edasalonexent for registration purposes, and other
statements containing the words “believes,” “anticipates,” “plans,”
“expects,” “may” and similar expressions, constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: uncertainties
inherent in the initiation and completion of preclinical studies
and clinical trials and clinical development of the Company’s
product candidates; whether interim results from a clinical trial
will be predictive of the final results of the trial or the results
of future trials; expectations for regulatory approvals to conduct
trials or to market products; availability of funding sufficient
for the Company’s foreseeable and unforeseeable operating expenses
and capital expenditure requirements; other matters that could
affect the availability or commercial potential of the Company’s
product candidates; and general economic and market conditions and
other factors discussed in the “Risk Factors” section of the
Company’s Quarterly Report on Form 10-Q for the quarter ended
September 30, 2018, which is on file with the Securities and
Exchange Commission, and in other filings that the Company may make
with the Securities and Exchange Commission in the future. In
addition, the forward-looking statements included in this press
release represent the Company’s views as of the date of this press
release. The Company anticipates that subsequent events and
developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing the Company’s views as of
any date subsequent to the date of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190104005063/en/
Investor and Media ContactAndrea
MatthewsCatabasis Pharmaceuticals, Inc.T: (617)
349-1971amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Apr 2023 to Apr 2024